 |
|
Diuretic Therapy, the  -Adducin Gene Variant, and the Risk of Myocardial Infarction or Stroke in Persons With Treated Hypertension
Bruce M. Psaty, MD,PhD;
Nicholas L. Smith, PhD;
Susan R. Heckbert, MD,PhD;
Hans L. Vos, PhD;
Rozenn N. Lemaitre, PhD;
Alexander P. Reiner, MD,MPH;
David S. Siscovick, MD,MPH;
Joshua Bis;
Thomas Lumley, PhD;
W. T. Longstreth, Jr, MD,MPH;
Frits R. Rosendaal, MD,PhD
JAMA. 2002;287:1680-1689.
Context A genetic variant in  -adducin has been associated with renal sodium reabsorption and salt-sensitive hypertension. Whether this genetic variant modifies the effect of diuretic therapy on the incidence of myocardial infarction (MI) and stroke is unknown.
Objectives To estimate the interaction between -adducin and diuretic therapy on the risk of MI or stroke. Specifically, we hypothesized that in participants with treated hypertension, the risk of MI or stroke associated with diuretic use would be lower in carriers of the adducin variant than in carriers of the adducin wild-type genotype.
Design, Setting, and Participants Population-based case-control study of patients enrolled in a health maintenance organization, treated pharmacologically for hypertension, and genotyped as homozygous carriers of the adducin wild-type genotype or carriers of 1 or 2 copies of the Trp460 variant allele. Cases had a first nonfatal MI (n = 206) or stroke (n = 117) between January 1995 and December 1998. Controls (n = 715) were a stratified random sample of pharmacologically treated hypertensive patients who were matched to MI cases by age, sex, and calendar year.
Main Outcome Measure Risk of the combined outcome of first nonfatal MI or stroke.
Results The adducin variant was present in more than one third of the participants. Among the 653 carriers of the adducin wild-type genotype, diuretic therapy was not associated with the risk of MI or stroke (odds ratio [OR], 1.09; 95% confidence interval [CI], 0.78-1.52). Among the 385 carriers of the adducin variant allele, diuretic therapy was associated with a lower risk of the combined outcome of MI and stroke than other antihypertensive therapies (OR, 0.49; 95% CI, 0.32-0.77). The OR in carriers of the adducin variant was less than half of the OR in carriers of the wild-type genotype (P = .005). The case-control synergy index (SI) was 0.45 (95% CI, 0.26-0.79) for the combined outcome of MI and stroke. The point estimates of the diuretic-adducin interaction were similar in separate analyses of MI (SI, 0.41; 95% CI, 0.21-0.80) and stroke (SI, 0.53; 95% CI, 0.24-1.19). The diuretic-adducin interaction was not confounded by traditional cardiovascular risk factors, was specific to diuretic therapy but not present for other major antihypertensive drug classes, and did not differ substantially between subgroups defined by age, sex, race, diabetes, and history of cardiovascular disease.
Conclusions In carriers of the adducin variant, diuretic therapy was associated with a lower risk of combined MI or stroke than other antihypertensive therapies. If these findings are confirmed in other studies, this large subgroup of the hypertensive population may be especially likely to benefit from low-dose diuretic therapy.
Author Affiliations: Cardiovascular Health Research Unit, Departments of Epidemiology (Drs Psaty, Smith, Heckbert, Reiner, Rosendaal and Mr Bis), Medicine (Drs Psaty, Lemaitre, Siscovick), Biostatistics (Dr Lumley), Neurology (Dr Longstreth), and Health Services (Dr Psaty), University of Washington, Seattle; and Departments of Hematology (Drs Vos and Rosendaal) and Clinical Epidemiology (Dr Rosendaal), Leiden University Medical Center, Leiden, the Netherlands.
RELATED ARTICLE
April 3, 2002
JAMA. 2002;287(13):1735-1736.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Physiological Interaction Between {alpha}-Adducin and WNK1-NEDD4L Pathways on Sodium-Related Blood Pressure Regulation
Manunta et al.
Hypertension 2008;52:366-372.
ABSTRACT
| FULL TEXT
{alpha}-Adducin Gly460Trp Variant Increases the Risk of Stroke in Hypertensive Dutch Women
Zafarmand et al.
Hypertension 2008;51:1665-1670.
ABSTRACT
| FULL TEXT
Role of rat {alpha} adducin in angiogenesis: Null effect of the F316Y polymorphism
Cappuzzello et al.
Cardiovasc Res 2007;75:608-617.
ABSTRACT
| FULL TEXT
Renin-Angiotensin System Haplotypes and the Risk of Myocardial Infarction and Stroke in Pharmacologically Treated Hypertensive Patients
Marciante et al.
Am J Epidemiol 2007;166:19-27.
ABSTRACT
| FULL TEXT
Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group
Arnett et al.
Circulation 2007;115:2878-2901.
ABSTRACT
| FULL TEXT
Cardiovascular Pharmacogenomics
Momary
Journal of Pharmacy Practice 2007;20:265-276.
ABSTRACT
Angiotensin-Converting Enzyme I/D and {alpha}-Adducin Gly460Trp Polymorphisms: From Angiotensin-Converting Enzyme Activity to Cardiovascular Outcome
Li et al.
Hypertension 2007;49:1291-1297.
ABSTRACT
| FULL TEXT
Logic Regression for Analysis of the Association between Genetic Variation in the Renin-Angiotensin System and Myocardial Infarction or Stroke
Kooperberg et al.
Am J Epidemiol 2007;165:334-343.
ABSTRACT
| FULL TEXT
{alpha}-Adducin Polymorphism, Atherosclerosis, and Cardiovascular and Cerebrovascular Risk
van Rijn et al.
Stroke 2006;37:2930-2934.
ABSTRACT
| FULL TEXT
Pharmacogenomics and Pharmacogenetics of Hypertension: Update and Perspectives--The Adducin Paradigm
Manunta and Bianchi
J. Am. Soc. Nephrol. 2006;17:S30-S35.
ABSTRACT
| FULL TEXT
Importance of Race/Ethnicity in Clinical Trials: Lessons From the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Taylor et al.
Circulation 2005;112:3654-3666.
FULL TEXT
Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: from gene polymorphism to clinical symptoms
Bianchi
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005;289:R1536-R1549.
ABSTRACT
| FULL TEXT
Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics
Ginsburg et al.
J Am Coll Cardiol 2005;46:1615-1627.
ABSTRACT
| FULL TEXT
Cardiovascular Risk in Relation to {alpha}-Adducin Gly460Trp Polymorphism and Systolic Pressure: A Prospective Population Study
Li et al.
Hypertension 2005;46:527-532.
ABSTRACT
| FULL TEXT
Challenges in Systematic Reviews That Evaluate Drug Efficacy or Effectiveness
Santaguida et al.
ANN INTERN MED 2005;142:1066-1072.
ABSTRACT
| FULL TEXT
Cardiovascular pharmacogenomics
Johnson and Cavallari
Exp Physiol 2005;90:283-289.
ABSTRACT
| FULL TEXT
Links Between Dietary Salt Intake, Renal Salt Handling, Blood Pressure, and Cardiovascular Diseases
Meneton et al.
Physiol. Rev. 2005;85:679-715.
ABSTRACT
| FULL TEXT
Adducin Polymorphism: Detection and Impact on Hypertension and Related Disorders
Bianchi et al.
Hypertension 2005;45:331-340.
ABSTRACT
| FULL TEXT
Hypertension-Linked Mutation in the Adducin {alpha}-Subunit Leads to Higher AP2-{micro}2 Phosphorylation and Impaired Na+,K+-ATPase Trafficking in Response to GPCR Signals and Intracellular Sodium
Efendiev et al.
Circ. Res. 2004;95:1100-1108.
ABSTRACT
| FULL TEXT
Clinically Translated Ischemic Stroke Genomics
Meschia
Stroke 2004;35:2735-2739.
ABSTRACT
| FULL TEXT
Atherosclerotic Vascular Disease Conference: Writing Group II: Risk Factors
Smith et al.
Circulation 2004;109:2613-2616.
FULL TEXT
Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study
Tobin et al.
Eur Heart J 2004;25:459-467.
ABSTRACT
| FULL TEXT
Low-Salt Diet and Diuretic Effect on Blood Pressure and Organ Damage
Manunta and Bianchi
J. Am. Soc. Nephrol. 2004;15:S43-46.
ABSTRACT
| FULL TEXT
Cardiology: the past, the present, and the future
Braunwald
J Am Coll Cardiol 2003;42:2031-2041.
FULL TEXT
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Chobanian et al.
Hypertension 2003;42:1206-1252.
ABSTRACT
| FULL TEXT
Susceptibility Genes for Hypertension and Renal Failure
Freedman
J. Am. Soc. Nephrol. 2003;14:S192-194.
ABSTRACT
| FULL TEXT
Genomics and Medicine: Distraction, Incremental Progress, or the Dawn of a New Age?
Cooper and Psaty
ANN INTERN MED 2003;138:576-580.
ABSTRACT
| FULL TEXT
Outcome beyond blood pressure control?
Staessen et al.
Eur Heart J 2003;24:504-514.
FULL TEXT
Cardiovascular Pharmacogenomics: Current Status, Future Prospects
Anderson et al.
J CARDIOVASC PHARMACOL THER 2003;8:71-83.
ABSTRACT
Pharmacogenomics -- Drug Disposition, Drug Targets, and Side Effects
Evans and McLeod
NEJM 2003;348:538-549.
FULL TEXT
Genetic Marker for Which Hypertensive Patients Benefit Most from Diuretics
Journal Watch Cardiology 2002;2002:3-3.
FULL TEXT
Pharmacogenomics in Endocrinology
Hockett et al.
J. Clin. Endocrinol. Metab. 2002;87:2495-2499.
FULL TEXT
Basic Science and Translational Research in JAMA
Fontanarosa and DeAngelis
JAMA 2002;287:1728-1728.
FULL TEXT
|
